Product Description
Cell permeable. A potent and selective inhibitor of the cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5. Inhibits cell cycle progression at the G1/S and G2/M transitions. BLI is an important tool for probing the cellular roles of CDKs. It blocks Fas-induced apoptosis and displays antitumor activity.
Butyrolactone I is a potent and selective inhibitor of the cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5. Inhibits cell cycle progression at the G1/S and G2/M transitions.
Biovision | 1690 | Butyrolactone I DataSheet
Alternate Name/Synonyms: BLI, BL-I
Appearance: White solid
Formulation: N/A
CAS Number: 87414-49-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₄H₂₄O₇
Molecular Weight: 424.44
Cell-Permeable?: Yes
Purity: ≥99% by HPLC
Solubilities: DMSO (10 mg/ml) and Ethanol (25 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A CDK inhibitor
MDL Number: MFCD03453074
PubChem CID: 3035414
SMILES: CC(=CCC1=C(C=CC(=C1)COC(=O)C2(C(=C(C(=O)O2)O)C3=CC=C(C=C3)O)C)O)C
InChi: InChI=1S/C24H24O7/c1-14(2)4-6-17-12-15(5-11-19(17)26)13-30-23(29)24(3)20(21(27)22(28)31-24)16-7-9-18(25)10-8-16/h4-5,7-12,25-27H,6,13H2, 1-3H3/t24-/m1/s1
InChi Key: FPVUCBMBMUHRDX-XMMPIXPASA-N